Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics

Aberrant glycosylation is a hallmark of a cancer cell. One prevalent alteration is an enrichment in α2,6-linked sialylation of N-glycosylated proteins, a modification directed by the ST6GAL1 sialyltransferase. ST6GAL1 is upregulated in many malignancies including ovarian cancer. Prior studies have shown that the addition of α2,6 sialic acid to the Epidermal Growth Factor Receptor (EGFR) activates this receptor, although the mechanism was largely unknown. To investigate the role of ST6GAL1 in EGFR activation, ST6GAL1 was overexpressed in the OV4 ovarian cancer line, which lacks endogenous ST6GAL1, or knocked down in the OVCAR-3 and OVCAR-5 ovarian cancer lines, which have robust ST6GAL1 expression. Cells with high expression of ST6GAL1 displayed increased activation of EGFR and its downstream signaling targets, AKT and NFκB. Using biochemical and microscopy approaches, including Total Internal Reflection Fluorescence (TIRF) microscopy, we determined that the α2,6 sialylation of EGFR promoted its dimerization and higher order oligomerization. Additionally, ST6GAL1 activity was found to modulate EGFR trafficking dynamics following EGF-induced receptor activation. Specifically, EGFR sialylation enhanced receptor recycling to the cell surface following activation while simultaneously inhibiting lysosomal degradation. 3D widefield deconvolution microscopy confirmed that in cells with high ST6GAL1 expression, EGFR exhibited greater co-localization with Rab11 recycling endosomes and reduced co-localization with LAMP1-positive lysosomes. Collectively, our findings highlight a novel mechanism by which α2,6 sialylation promotes EGFR signaling by facilitating receptor oligomerization and recycling.

[1]  A. Hjelmeland,et al.  ST6Gal1: Oncogenic signaling pathways and targets , 2022, Frontiers in Molecular Biosciences.

[2]  Jiun-Jie Shie,et al.  A Multiscale Molecular Dynamic Analysis Reveals the Effect of Sialylation on EGFR Clustering in a CRISPR/Cas9-Derived Model , 2022, International journal of molecular sciences.

[3]  Jihye Hwang,et al.  ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression , 2022, bioRxiv.

[4]  Jingchao Li,et al.  O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Tejeshwar C. Rao,et al.  Tension Gauge Tether Probes for Quantifying Growth Factor Mediated Integrin Mechanics and Adhesion. , 2022, Journal of visualized experiments : JoVE.

[6]  K. Salaita,et al.  ST6Gal-I–mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion , 2022, The Journal of biological chemistry.

[7]  Motoko Takahashi,et al.  Role of glycosyltransferases in carcinogenesis; growth factor signaling and EMT/MET programs , 2022, Glycoconjugate Journal.

[8]  A. Albergaria,et al.  Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells , 2021, Cellular Oncology.

[9]  K. Yoshihara,et al.  Biological significance of KRAS mutant allele expression in ovarian endometriosis , 2021, Cancer science.

[10]  Jihye Hwang,et al.  Regulation of ST6GAL1 sialyltransferase expression in cancer cells. , 2020, Glycobiology.

[11]  D. Crossman,et al.  Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells , 2020, The Journal of biological chemistry.

[12]  Vanessa C. Muñoz,et al.  GOLPH3 Regulates EGFR in T98G Glioblastoma Cells by Modulating Its Glycosylation and Ubiquitylation , 2020, International journal of molecular sciences.

[13]  S. Bellis,et al.  Modulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover , 2020, The Journal of Biological Chemistry.

[14]  Yanfang Qiu,et al.  Rab25-Mediated EGFR Recycling Causes Tumor Acquired Radioresistance , 2020, iScience.

[15]  Karen E. Livermore,et al.  ST6GAL1: A key player in cancer , 2019, Oncology letters.

[16]  L. Jia,et al.  The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia , 2019, Journal of Experimental & Clinical Cancer Research.

[17]  Masanori Kato,et al.  TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X , 2019, Molecular Cancer Therapeutics.

[18]  C. Willey,et al.  Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death , 2018, Journal of Ovarian Research.

[19]  F. dall’Olio,et al.  Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling , 2018, International journal of molecular sciences.

[20]  S. Bellis,et al.  ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor , 2017, The Journal of Biological Chemistry.

[21]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[22]  A. Kiyatkin,et al.  EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics , 2017, Cell.

[23]  H. Ditzel,et al.  Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer , 2017, Nature Communications.

[24]  C. Verma,et al.  Role of N‐glycosylation in EGFR ectodomain ligand binding , 2017, Proteins.

[25]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[26]  A. Rehemtulla,et al.  Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors , 2016, Oncotarget.

[27]  Jianchun Chen,et al.  Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease. , 2016, Physiological reviews.

[28]  E. Isacoff,et al.  Molecular basis for multimerization in the activation of the epidermal growth factor receptor , 2016, eLife.

[29]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[30]  A. Chariot,et al.  EGFR and NF-κB: partners in cancer. , 2015, Trends in molecular medicine.

[31]  Chi‐Huey Wong,et al.  Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition , 2015, Proceedings of the National Academy of Sciences.

[32]  J. Gu,et al.  Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers , 2015, Molecules.

[33]  Sourav Bandyopadhyay,et al.  NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. , 2015, Cell reports.

[34]  I. Vattulainen,et al.  N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes , 2015, Proceedings of the National Academy of Sciences.

[35]  Chuan-Fa Chang,et al.  Lewisy Promotes Migration of Oral Cancer Cells by Glycosylation of Epidermal Growth Factor Receptor , 2015, PloS one.

[36]  J. Schlessinger,et al.  Receptor tyrosine kinases: legacy of the first two decades. , 2014, Cold Spring Harbor perspectives in biology.

[37]  C. Futter,et al.  EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.

[38]  H. Gan,et al.  The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered , 2013, The FEBS journal.

[39]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[40]  M. Schultz,et al.  Regulation of the metastatic cell phenotype by sialylated glycans , 2012, Cancer and Metastasis Reviews.

[41]  Minyoung Lee,et al.  Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. , 2012, Biochemical pharmacology.

[42]  D. Bullard,et al.  ST6Gal-I Regulates Macrophage Apoptosis via α2-6 Sialylation of the TNFR1 Death Receptor* , 2011, The Journal of Biological Chemistry.

[43]  A. Ballabio,et al.  Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance , 2011, Developmental cell.

[44]  Chien-Yu Chen,et al.  Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells , 2011, Proceedings of the National Academy of Sciences.

[45]  S. Bellis,et al.  Sialylation of the Fas Death Receptor by ST6Gal-I Provides Protection against Fas-mediated Apoptosis in Colon Carcinoma Cells* , 2011, The Journal of Biological Chemistry.

[46]  S. Simon,et al.  Imaging with total internal reflection fluorescence microscopy for the cell biologist , 2010, Journal of Cell Science.

[47]  Tilman Schneider-Poetsch,et al.  Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin , 2010, Nature chemical biology.

[48]  J. Marth,et al.  α2,6-Sialic Acid on Platelet Endothelial Cell Adhesion Molecule (PECAM) Regulates Its Homophilic Interactions and Downstream Antiapoptotic Signaling* , 2010, The Journal of Biological Chemistry.

[49]  S. Bellis,et al.  ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function , 2008, Journal of ovarian research.

[50]  Y. Zhuo,et al.  Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms. , 2008, Experimental cell research.

[51]  F. Cordelières,et al.  A guided tour into subcellular colocalization analysis in light microscopy , 2006, Journal of microscopy.

[52]  A. Beth,et al.  Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor. , 2005, Biochemistry.

[53]  Richard M Caprioli,et al.  Characterization of glycosylation sites of the epidermal growth factor receptor. , 2003, Biochemistry.

[54]  L. Baum,et al.  The ST6Gal I Sialyltransferase Selectively ModifiesN-Glycans on CD45 to Negatively Regulate Galectin-1-induced CD45 Clustering, Phosphatase Modulation, and T Cell Death* , 2003, The Journal of Biological Chemistry.

[55]  Zhixiang Wang,et al.  Endosomal Signaling of Epidermal Growth Factor Receptor Stimulates Signal Transduction Pathways Leading to Cell Survival , 2002, Molecular and Cellular Biology.

[56]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[57]  Y. Ikeda,et al.  The Asn-420-linked Sugar Chain in Human Epidermal Growth Factor Receptor Suppresses Ligand-independent Spontaneous Oligomerization , 2000, The Journal of Biological Chemistry.

[58]  M. Zerial,et al.  Rab11 regulates recycling through the pericentriolar recycling endosome , 1996, The Journal of cell biology.

[59]  R. Chapkin,et al.  Analysis of epidermal growth factor receptor dimerization by BS³ cross-linking. , 2015, Methods in molecular biology.

[60]  A. Varki,et al.  Glycosylation Changes in Cancer , 2009 .

[61]  S. Bellis,et al.  A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering beta1 integrin sialylation. , 2005, Journal of Biological Chemistry.